LeonaBio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $17.5M | $70.7M | $93.8M | $61.5M | $42.8M |
| Operating income | -$102.3M | -$100.9M | -$125.5M | -$104.0M | -$64.0M |
| Interest expense | — | — | — | — | $3,000 |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$105.6M | -$96.9M | -$117.7M | -$95.6M | -$54.9M |
| Balance Sheet | |||||
| Cash and equivalents | $69.3M | $48.4M | $90.6M | $96.0M | $110.5M |
| Current assets | $89.5M | $54.8M | $154.7M | $207.5M | $260.8M |
| Total assets | $92.2M | $58.8M | $160.2M | $258.2M | $332.0M |
| Current liabilities | $47.5M | $13.1M | $28.8M | $21.4M | $9.3M |
| Total liabilities | $64.4M | $13.9M | $30.1M | $23.0M | $10.9M |
| Stockholders' equity | $27.8M | $44.8M | $130.2M | $235.1M | $321.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$45.7M | -$97.2M | -$100.8M | -$72.5M | -$43.1M |
| Depreciation and amortization | $972,000 | $970,000 | $969,000 | $845,000 | $479,000 |
| Stock-based compensation | $6.1M | $11.0M | $10.6M | $10.6M | $4.6M |
| Capital expenditure | — | $33,000 | $304,000 | $1.1M | $1.6M |
| Free cash flow | — | -$97.2M | -$101.1M | -$73.6M | -$44.7M |
Shares outstanding 9.4M · Free float 38.6%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.